Progress on S-1 in the treatment of advanced breast cancer

ZHENG Ting; QIAN Qijun

doi:10.3969/j.issn.1006-0111.2015.06.021

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 33 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2015 > 33(6): 557-560

ZHENG Ting, QIAN Qijun. Progress on S-1 in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021

Citation:

ZHENG Ting, QIAN Qijun. Progress on S-1 in the treatment of advanced breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 557-560. doi: 10.3969/j.issn.1006-0111.2015.06.021

Progress on S-1 in the treatment of advanced breast cancer

doi: 10.3969/j.issn.1006-0111.2015.06.021

ZHENG Ting¹,
QIAN Qijun^2
,

1.
First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China;Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China
2.
Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

Received Date: 2015-02-09
Rev Recd Date: 2015-06-04

Abstract

S-1 is the third generation of fluorouracil derivative anti-cancer agent with small side effects, efficacy, and drug delivery is convenient.In a large number of clinical trials and continuous clinical application, it showed the good effect for the treatment of advanced breast cancer, which was expected to become the first-line chemotherapy drug for breast cancer treatment in the future.
- S-1,
- advanced breast cancer,
- chemotherapy drug

References

[1]	Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2]	邬晓敏,章烨,朱为民,等.培美曲塞联合顺铂治疗晚期乳腺癌的疗效观察[J].中国癌症杂志,2011,21(2):159-160.
[3]	汪进良,焦顺昌.替吉奥用于非小细胞肺癌治疗的研究及展望[J].中华医学杂志,2010,90(36):2582-2585.
[4]	Muro K,Boku N,Shimada Y,et al.Irinotecan plus S-1(IRIS)versus fluorouracil and folinic acid plus irinotecan(FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer:a randomised phase 2/3 non-inferiority study(FIRIS study)[J].Lancet Oncol,2010,11(9):853-860.
[5]	Ueno H,Okusaka T,Furuse J,et al.Multicenter phase Ⅱ study of gemcitabine and S-1 combination therapy(GSTherapy) in patients with metastatic pancreatic cancer[J].Jpn J Clin Oncol,2011,41(8):953-958.
[6]	Saito Y,Oshitanai R,Terao M,et al.Post-marketing safety evaluation of S-1 in patients withinoperable or recurrent breast cancer: especially in patients treated with S-1 1 trastuzumab[J].Jpn J Clin Oncol, 2011,41(9):1051-1058.
[7]	Yamamoto Y, Nishimura R, Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer-an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG) [J].GanTo Kagaku Ryoho,2014,41(10):1221-1225.
[8]	马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502.
[9]	Malet-Martino M,Martino R. Clinical studies of three oralprodrugs of 5-fluorouracil(capecitabine,UFT,S-1):a review[J].Oncologist,2002,7(4):288-323.
[10]	Ito Y,Osaki Y,Tokudome N,et al.Efficacy of S-1 in heavilypretreated patients with metastatic breast cancer:cross-resistance to capecitabine[J].Breast Cancer,2009,16(2):126.
[11]	Saeki T,Takashima S,Sano M,et al.Aphase Ⅱ study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group[J].Breast Cancer,2004,11(2):194-202.
[12]	Shien T,Shimizu C,Akashi-Tanakal S,et al.Clinical efficacy of S-1 in pretreated metastatic breast cancer patients[J].Jpn J Clin Oncol,2008,38(3):172-175.
[13]	Vici P,Giotta F,Di Lauro L,et al.A multicenter phase Ⅱ randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer:a gruppo oncologico Italia meridionale study[J].Oncology,201l,81(3-4):230-236.
[14]	Lee JL,Kang YK,Kang HJ,et al.A randomised multicentre phaseⅡ trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J].Br J Cancer,2008,99(4):584-590.
[15]	Yamamoto D,Iwase S,Yoshida H,et al.Efficacy of S-1 in patients with capecitabine-resistantbreast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial[J].Anticancer Res,2010,30(9): 3827-3831.
[16]	Mukai H, Takashima T, HozumiY,et al.Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC) [J].Jpn J Clin Oncol, 2010,40(8):811-814.
[17]	Nohara T,Iwamoto M,Sumiyoshi K, et al.Examination of the clinical usefulness of TS-1 in locally recurrent breast cancer[J]. Oncol Let,2010,1(4): 669-672.
[18]	Yamamoto Y, Nishimura R, Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer-an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].GanTo Kagaku Ryoho. 2014,41(10):1221-1225.
[19]	Kobayashi Y, Kadoya T, Kanno E,et al.A resected case of complete response after treatment with S-1 for recurrent squamous cell carcinoma component of the breast[J].GanTo Kagaku Ryoho,2012,39(9):1403-1406.
[20]	Tazawa K, Tsuchiya Y, Shinbo M,et al.Effective chemotherapy with S-1 alone in a patient with lung metastases of breast cancer[J].GanTo Kagaku Ryoho, 2011,38(3):423-425.
[21]	Yoshida H, Yamamoto D, Kanematsu S,et al.A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy[J].GanTo Kagaku Ryoho,2010,37(13):2901-2903.
[22]	Takeyama H, Kyoda S, Yamashita A,et al.A case of repeated bone metastases of breast carcinoma successfully treated by S-1 chemotherapy[J].GanTo Kagaku Ryoho,2011,38(11):1873-1875.
[23]	Mori T, Yoshimura G, Ito D,et al.Three cases effectively treated with S-1 therapy for liver metastasis of breast cancer in long term[J].GanTo Kagaku Ryoho,2011,38(9):1495-1498.
[24]	Kubo H, Kijima D, Tada K,et al.A case of anthracycline- and taxane-resistant recurrent advanced breast cancer successfully treated with S-1 monotherapy[J].GanTo Kagaku Ryoho,2010,37(7):1325-1327.
[25]	Kato M, Kitayama J, Yamaguchi H,et al.Three cases of metastatic breast cancer effectively treated with S-1 therapy[J].GanTo Kagaku Ryoho,2010,37(5):903-906.
[26]	Aoyagi H, Kaneko J, Makinose T,et al.A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies[J].GanTo Kagaku Ryoho,2009,36(12):2474-2476.
[27]	Takashima T, Nakayama T, Yoshidome K,et al.Phase Ⅱ study of s-1 in combination with trastuzumab for HER2-positive metastatic breast cancer[J].Anticancer Res, 201434: 3583-3588 .
[28]	Ishida K.A case of recurrent breast cancer with liver metastases showing good response to combination therapy with S-1plus trastuzumab[J].GanTo Kagaku Ryoho,2013,40(10):1385-1387.
[29]	Nakayama T, Morita S, Takashima T,et al.Phase Ⅰ study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer[J].Anticancer Res,2011,31(9):3035-3039.
[30]	Tokugawa T, Kobayashi A, Okubo K,et al.A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab[J].GanTo Kagaku Ryoho,2009,36(4):679-682.

Proportional views

通讯作者: 陈斌, [email protected]

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(3805) PDF downloads(183) Cited by()

Proportional views

Progress on S-1 in the treatment of advanced breast cancer

1. First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China;Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

2. Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

Received Date: 2015-02-09

Rev Recd Date: 2015-06-04

Key words:

Abstract: S-1 is the third generation of fluorouracil derivative anti-cancer agent with small side effects, efficacy, and drug delivery is convenient.In a large number of clinical trials and continuous clinical application, it showed the good effect for the treatment of advanced breast cancer, which was expected to become the first-line chemotherapy drug for breast cancer treatment in the future.

HTML

Reference (30)

[1]	Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2]	邬晓敏,章烨,朱为民,等.培美曲塞联合顺铂治疗晚期乳腺癌的疗效观察[J].中国癌症杂志,2011,21(2):159-160.
[3]	汪进良,焦顺昌.替吉奥用于非小细胞肺癌治疗的研究及展望[J].中华医学杂志,2010,90(36):2582-2585.
[4]	Muro K,Boku N,Shimada Y,et al.Irinotecan plus S-1(IRIS)versus fluorouracil and folinic acid plus irinotecan(FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer:a randomised phase 2/3 non-inferiority study(FIRIS study)[J].Lancet Oncol,2010,11(9):853-860.
[5]	Ueno H,Okusaka T,Furuse J,et al.Multicenter phase Ⅱ study of gemcitabine and S-1 combination therapy(GSTherapy) in patients with metastatic pancreatic cancer[J].Jpn J Clin Oncol,2011,41(8):953-958.
[6]	Saito Y,Oshitanai R,Terao M,et al.Post-marketing safety evaluation of S-1 in patients withinoperable or recurrent breast cancer: especially in patients treated with S-1 1 trastuzumab[J].Jpn J Clin Oncol, 2011,41(9):1051-1058.
[7]	Yamamoto Y, Nishimura R, Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer-an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG) [J].GanTo Kagaku Ryoho,2014,41(10):1221-1225.
[8]	马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502.
[9]	Malet-Martino M,Martino R. Clinical studies of three oralprodrugs of 5-fluorouracil(capecitabine,UFT,S-1):a review[J].Oncologist,2002,7(4):288-323.
[10]	Ito Y,Osaki Y,Tokudome N,et al.Efficacy of S-1 in heavilypretreated patients with metastatic breast cancer:cross-resistance to capecitabine[J].Breast Cancer,2009,16(2):126.
[11]	Saeki T,Takashima S,Sano M,et al.Aphase Ⅱ study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group[J].Breast Cancer,2004,11(2):194-202.
[12]	Shien T,Shimizu C,Akashi-Tanakal S,et al.Clinical efficacy of S-1 in pretreated metastatic breast cancer patients[J].Jpn J Clin Oncol,2008,38(3):172-175.
[13]	Vici P,Giotta F,Di Lauro L,et al.A multicenter phase Ⅱ randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer:a gruppo oncologico Italia meridionale study[J].Oncology,201l,81(3-4):230-236.
[14]	Lee JL,Kang YK,Kang HJ,et al.A randomised multicentre phaseⅡ trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer[J].Br J Cancer,2008,99(4):584-590.
[15]	Yamamoto D,Iwase S,Yoshida H,et al.Efficacy of S-1 in patients with capecitabine-resistantbreast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial[J].Anticancer Res,2010,30(9): 3827-3831.
[16]	Mukai H, Takashima T, HozumiY,et al.Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC) [J].Jpn J Clin Oncol, 2010,40(8):811-814.
[17]	Nohara T,Iwamoto M,Sumiyoshi K, et al.Examination of the clinical usefulness of TS-1 in locally recurrent breast cancer[J]. Oncol Let,2010,1(4): 669-672.
[18]	Yamamoto Y, Nishimura R, Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer-an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].GanTo Kagaku Ryoho. 2014,41(10):1221-1225.
[19]	Kobayashi Y, Kadoya T, Kanno E,et al.A resected case of complete response after treatment with S-1 for recurrent squamous cell carcinoma component of the breast[J].GanTo Kagaku Ryoho,2012,39(9):1403-1406.
[20]	Tazawa K, Tsuchiya Y, Shinbo M,et al.Effective chemotherapy with S-1 alone in a patient with lung metastases of breast cancer[J].GanTo Kagaku Ryoho, 2011,38(3):423-425.
[21]	Yoshida H, Yamamoto D, Kanematsu S,et al.A case of multi-drug resistant breast cancer with liver metastasis treated effectively by S-1 monotherapy[J].GanTo Kagaku Ryoho,2010,37(13):2901-2903.
[22]	Takeyama H, Kyoda S, Yamashita A,et al.A case of repeated bone metastases of breast carcinoma successfully treated by S-1 chemotherapy[J].GanTo Kagaku Ryoho,2011,38(11):1873-1875.
[23]	Mori T, Yoshimura G, Ito D,et al.Three cases effectively treated with S-1 therapy for liver metastasis of breast cancer in long term[J].GanTo Kagaku Ryoho,2011,38(9):1495-1498.
[24]	Kubo H, Kijima D, Tada K,et al.A case of anthracycline- and taxane-resistant recurrent advanced breast cancer successfully treated with S-1 monotherapy[J].GanTo Kagaku Ryoho,2010,37(7):1325-1327.
[25]	Kato M, Kitayama J, Yamaguchi H,et al.Three cases of metastatic breast cancer effectively treated with S-1 therapy[J].GanTo Kagaku Ryoho,2010,37(5):903-906.
[26]	Aoyagi H, Kaneko J, Makinose T,et al.A case of stage IV breast cancer responding to S-1 therapy after FEC and PTX therapies[J].GanTo Kagaku Ryoho,2009,36(12):2474-2476.
[27]	Takashima T, Nakayama T, Yoshidome K,et al.Phase Ⅱ study of s-1 in combination with trastuzumab for HER2-positive metastatic breast cancer[J].Anticancer Res, 201434: 3583-3588 .
[28]	Ishida K.A case of recurrent breast cancer with liver metastases showing good response to combination therapy with S-1plus trastuzumab[J].GanTo Kagaku Ryoho,2013,40(10):1385-1387.
[29]	Nakayama T, Morita S, Takashima T,et al.Phase Ⅰ study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer[J].Anticancer Res,2011,31(9):3035-3039.
[30]	Tokugawa T, Kobayashi A, Okubo K,et al.A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab[J].GanTo Kagaku Ryoho,2009,36(4):679-682.

Message Board

Progress on S-1 in the treatment of advanced breast cancer

doi: 10.3969/j.issn.1006-0111.2015.06.021

Abstract

References

Proportional views

通讯作者: 陈斌, [email protected]

Article Metrics

Related

Proportional views